Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 1.00 |
| ▸ | MEN1 | O00255 | 4/20 | 1.00 |
| ▸ | APAF1 | O14727 | 3/20 | 1.00 |
| ▸ | CASP3 | P42574 | 2/20 | 1.00 |
| ▸ | GAA | P10253 | 2/20 | 1.00 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 1.00 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 1.00 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.72 |
| ▸ | MAPT | P10636 | 3/20 | 0.72 |
| ▸ | HPGD | P15428 | 1/20 | 0.72 |
| ▸ | CASP6 | P55212 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | CASP1 | P29466 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | BLM | P54132 | 1/20 | 0.53 |
| ▸ | CASP7 | P55210 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3851940 | 0.87 | MEN1 (0.77) | KMT2AMEN1APAF1CASP3GAA | |
| SCHEMBL2586644 | 0.84 | KMT2A (1.00) | KMT2AMEN1APAF1CASP3GAA | |
| SCHEMBL29609544 | 0.84 | KMT2A (1.00) | KMT2AMEN1APAF1CASP3GAA | |
| SCHEMBL14938439 | 0.83 | MEN1 (0.71) | KMT2AMEN1APAF1CASP3GAA | |
| SCHEMBL12177051 | 0.83 | KMT2A (0.71) | KMT2AMEN1APAF1CASP3GAA | |
| SCHEMBL15627434 | 0.83 | MEN1 (0.70) | KMT2AMEN1APAF1CASP3GAA | |
| SCHEMBL45154 | 0.82 | CASP3 (0.88) | KMT2AMEN1APAF1CASP3GAA | |
| SCHEMBL30296449 | 0.82 | CASP3 (0.88) | KMT2AMEN1APAF1CASP3GAA | |
| SCHEMBL15276187 | 0.82 | KMT2A (0.70) | KMT2AMEN1APAF1CASP3GAA | |
| SCHEMBL2419059 | 0.82 | MEN1 (0.70) | KMT2AMEN1APAF1CASP3GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10653676-B2 | Small molecule inhibitors of USP1 deubiquitinating enzyme activity | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-05-19 | — | — | US | disclosed |
| US-20170202810-A1 | SMALL MOLECULE INHIBITORS OF USP1 DEUBIQUITINATING ENZYME ACTIVITY | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-07-20 | — | — | US | disclosed |
| US-9518032-B2 | Small molecule inhibitors of USP1 deubiquitinating enzyme activity | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-12-13 | — | — | US | disclosed |
| US-20130253005-A1 | SMALL MOLECULE INHIBITORS OF USP1 DEUBIQUITINATING ENZYME ACTIVITY | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2013-09-26 | — | — | US | disclosed |
| WO-2011137320-A2 | SMALL MOLECULE INHIBITORS OF USP1 DEUBIQUITINATING ENZYME ACTIVITY | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2011-11-03 | — | — | WO | disclosed |
| US-6583144-B2 | Piperazine substituted isoquinoline, 1,3-benzoxazine, or 1,3-benzothiazine derivatives; inhibitors against the biosynthesis of triglycerides and secretion of apolipoprotein b and treatment of hyperlipidemia | MEIJI SEIKA KAISHA, LTD. (JP) | 2003-06-24 | — | — | US | disclosed |
| US-20020156276-A1 | Nitrogen-containing heterocyclic compounds and therapeutic agents for hyperlipidemia comprising the same | OHKURA NAOTO (JP) | 2002-10-24 | — | — | US | disclosed |
| US-6417362-B1 | PIPERAZINE DERIVATIVES; ARTERIOSCLEROSIS, PANCREATITIS, AND CARDIOVASCULAR DISORDER TREATMENT; SIDE EFFECT REDUCTION | MEIJI SEIKA KAISHA, LTD. (JP) | 2002-07-09 | — | — | US | disclosed |
| EP-0999208-A1 | NITROGENOUS HETEROCYCLIC COMPOUNDS AND HYPERLIPEMIA REMEDY CONTAINING THE SAME | MEIJI SEIKA KAISHA LTD. (JP) | 2000-05-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130253005-A1 | SMALL MOLECULE INHIBITORS OF USP1 DEUBIQUITINATING ENZYME ACTIVITY | USP1, USP2, USP28 | KMT2A 639/4885MEN1 2034/4885APAF1 492/4885 |
| US-20020156276-A1 | Nitrogen-containing heterocyclic compounds and therapeutic agents for hyperlipidemia comprising the same | APOB, PNLIP, NR1H2 | KMT2A 2537/4885MEN1 3991/4885APAF1 4183/4885 |
| US-10653676-B2 | Small molecule inhibitors of USP1 deubiquitinating enzyme activity | USP1, USP2, USP28 | KMT2A 639/4885MEN1 2034/4885APAF1 492/4885 |
| US-20170202810-A1 | SMALL MOLECULE INHIBITORS OF USP1 DEUBIQUITINATING ENZYME ACTIVITY | USP1, USP2, USP28 | KMT2A 639/4885MEN1 2034/4885APAF1 492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.